Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()

Patients with type 2 diabetes mellitus (T2DM) are at increased risk for severe coronavirus disease 2019 (COVID-19) and related mortality. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have significant cardiovascular and renal benefits for patients with T2DM and related comorbidities. Their a...

Descripción completa

Detalles Bibliográficos
Autores principales: Patoulias, D., Boulmpou, A., Imprialos, K., Stavropoulos, K., Papadopoulos, C., Doumas, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). 2022
Materias:
Brief Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179096/
https://www.ncbi.nlm.nih.gov/pubmed/34167924
http://dx.doi.org/10.1016/j.rceng.2021.04.002
_version_ 1783703712738312192
author Patoulias, D.
Boulmpou, A.
Imprialos, K.
Stavropoulos, K.
Papadopoulos, C.
Doumas, M.
author_facet Patoulias, D.
Boulmpou, A.
Imprialos, K.
Stavropoulos, K.
Papadopoulos, C.
Doumas, M.
author_sort Patoulias, D.
collection PubMed
description Patients with type 2 diabetes mellitus (T2DM) are at increased risk for severe coronavirus disease 2019 (COVID-19) and related mortality. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have significant cardiovascular and renal benefits for patients with T2DM and related comorbidities. Their anti-inflammatory properties could be beneficial in these patients. This work provides less-biased estimates regarding the risk for respiratory tract infections and acute respiratory distress syndrome by performing the first significant meta-analysis of cardiovascular outcome trials in the literature. Notably, GLP-1-RAs do not seem to increase the risk for respiratory tract infection, pneumonia, or acute respiratory distress syndrome in patients with T2DM and cardiovascular comorbidities.
format Online
Article
Text
id pubmed-8179096
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI).
record_format MEDLINE/PubMed
spelling pubmed-81790962021-06-05 Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic() Patoulias, D. Boulmpou, A. Imprialos, K. Stavropoulos, K. Papadopoulos, C. Doumas, M. Rev Clin Esp (Barc) Brief Original Patients with type 2 diabetes mellitus (T2DM) are at increased risk for severe coronavirus disease 2019 (COVID-19) and related mortality. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have significant cardiovascular and renal benefits for patients with T2DM and related comorbidities. Their anti-inflammatory properties could be beneficial in these patients. This work provides less-biased estimates regarding the risk for respiratory tract infections and acute respiratory distress syndrome by performing the first significant meta-analysis of cardiovascular outcome trials in the literature. Notably, GLP-1-RAs do not seem to increase the risk for respiratory tract infection, pneumonia, or acute respiratory distress syndrome in patients with T2DM and cardiovascular comorbidities. Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). 2022-04 2021-06-05 /pmc/articles/PMC8179096/ /pubmed/34167924 http://dx.doi.org/10.1016/j.rceng.2021.04.002 Text en © 2021 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Brief Original
Patoulias, D.
Boulmpou, A.
Imprialos, K.
Stavropoulos, K.
Papadopoulos, C.
Doumas, M.
Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
title Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
title_full Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
title_fullStr Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
title_full_unstemmed Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
title_short Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
title_sort meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: useful implications for the covid-19 pandemic()
topic Brief Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179096/
https://www.ncbi.nlm.nih.gov/pubmed/34167924
http://dx.doi.org/10.1016/j.rceng.2021.04.002
work_keys_str_mv AT patouliasd metaanalysisevaluatingtheriskofrespiratorytractinfectionsandacuterespiratorydistresssyndromewithglucagonlikepeptide1receptoragonistsincardiovascularoutcometrialsusefulimplicationsforthecovid19pandemic
AT boulmpoua metaanalysisevaluatingtheriskofrespiratorytractinfectionsandacuterespiratorydistresssyndromewithglucagonlikepeptide1receptoragonistsincardiovascularoutcometrialsusefulimplicationsforthecovid19pandemic
AT imprialosk metaanalysisevaluatingtheriskofrespiratorytractinfectionsandacuterespiratorydistresssyndromewithglucagonlikepeptide1receptoragonistsincardiovascularoutcometrialsusefulimplicationsforthecovid19pandemic
AT stavropoulosk metaanalysisevaluatingtheriskofrespiratorytractinfectionsandacuterespiratorydistresssyndromewithglucagonlikepeptide1receptoragonistsincardiovascularoutcometrialsusefulimplicationsforthecovid19pandemic
AT papadopoulosc metaanalysisevaluatingtheriskofrespiratorytractinfectionsandacuterespiratorydistresssyndromewithglucagonlikepeptide1receptoragonistsincardiovascularoutcometrialsusefulimplicationsforthecovid19pandemic
AT doumasm metaanalysisevaluatingtheriskofrespiratorytractinfectionsandacuterespiratorydistresssyndromewithglucagonlikepeptide1receptoragonistsincardiovascularoutcometrialsusefulimplicationsforthecovid19pandemic

Ejemplares similares